Polypharmacy Clinical Trial
Official title:
Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal
This study protocol comprises three phases. The first two phases will be nationwide and aim to evaluate the prevalence and patterns of polypharmacy and assess the barriers and facilitators of deprescribing perceived by older adults, as well as their willingness to be deprescribed and to self-medicate. The third and last phase will be a non-pharmacological randomised clinical study to measure the impact of enablement of older adults in their willingness to be deprescribed and related quality of life.
Study design
This is a three-phase study:
1. Cross-sectional, analytical study of the prevalence and patterns of polypharmacy, namely
sociodemographic and clinical profiles (age, genre, area of residence and years of
study) and about medication (number of drugs and their active component), in older
adults attending Primary Care in Portugal.
2. Cross-sectional, triangulation study of older adults' perception of Barriers to and
Facilitators of Deprescribing, Willingness to be Deprescribed and Willingness to
Self-medicate.
3. Non-pharmacological randomised clinical study of the impact of enablement of older
adults in their willingness to be Deprescribed and related Quality of Life.
Phase I: prevalence of polypharmacy in older adults attending primary care in Portugal Design
Cross-sectional, analytical study.
Setting: Primary Care Centres in Portugal will be randomly selected from the five main-land
Portuguese Healthcare Administrative Regions and two Autonomous Regions (Madeira and Azores),
in order to obtain a national geographical representative sample.
Sample size Since the prevalence of polypharmacy in older adults is unknown, the
investigators used as base of population all older adults in Portugal. For the study, the
investigators used a 95% confidence interval (CI) and a maximum precision error of 5%, so a
minimum of 385 patients should be recruited.
Study procedures This phase of the study starts in November 2017. General Practitioners (GPs)
sampling is made according to existing files of previous projects adherent GPs, in other
epidemiological studies. After the selection of GPs, those who accept to participate will
recruit their own patients. Assuming that a GP will be able to include at least 6 patients in
a 3-week period, a total of 65 GPs will be enrolled in the study: 21 in North of Portugal
(31.7%), 16 in Centre of Portugal (24.7%), 18 in Lisbon-Tejo Valley (27.4%), 5 in Alentejo
(8.4%), 3 in Algarve (4.3%), 1 in Azores (1.6%) and 1 in Madeira (1.9%) in accordance with
the distribution of Portuguese old adult population (≥65 years) in Portugal according with
Pordata (www.pordata.pt).
Enrolled GPs will be instructed to collect all necessary data about their patients meeting
the eligibility criteria.
Data collection The collection of the data will occur in November 2017. GPs will be
responsible for collecting all data about patients' sociodemographic characteristics, as well
as morbidity and medication, during their consultations.
Data will be electronically stored in a database specifically designed for this study using
MS Access 2010. Data will be encrypted and password protected. Information will be treated in
strict confidentiality to protect the privacy of patients. The investigators will have no
access to the data of the patient, except the one provided by the GP meaning that the only
person to know who is being studied is the GP.
Before the collection of data, there will be online reunions with the GPs participating in
the study.
Statistical analysis A descriptive analysis will be performed to all study variables, namely
the number of valid observations, mean±SD, median and range for quantitative variables and
absolute and relative frequencies for qualitative variables. Prevalence of polypharmacy
(considering definition: ≥5 drugs vs ≥ the median number) will be calculated together with
corresponding 95% CI. Moreover, the prevalence of polypharmacy will be estimated by
subgroups, namely age, gender, residence area and formal education. Univariate analysis will
be conducted to study the associations between those characteristics and polypharmacy using
χ2 test (qualitative characteristics) or t test/Mann-Whitney (quantitative characteristics).
Multiple logistic regressions will be carried out considering the presence of polypharmacy as
the dependent variable and patients' characteristics as the independent variables in order to
calculate odds ratio (ORs) and corresponding 95% CI. Total number of drugs taken by patient
and their pharmacological classes will also be summarised together with 95% CI, and multiple
regressions may be performed to analyse its association with patients' characteristics. All
tests will be two-sided using a significance level of 0.05. Statistical analysis will be
conducted using SPSS V.23.0 or higher.
Phase II: patients' perception of barriers to and facilitators of deprescribing, willingness
to be deprescribed and actual self-medication in adult patients with polypharmacy attending
primary care in Portugal Objectives To assert reasons and facilitators, willingness to be
deprescribed and actual self-medication
Design Cross-sectional, analytical study.
Setting It will be the same of the phase I.
Sample size A minimum of 385 patients will be included in phase II in order to obtain a
sample with a 95% CI and a maximum precision error of 5%.
Study procedures This phase of the study is expected to start in June 2018. Again, GPs
sampling will be made according to existing files and those who accept to participate will
recruit their own patients. Patients from phase I can be enrolled in phase II. Assuming that
a GP will be able to include at least 6 patients in a 3-week period, a total of 65 GPs has to
be enrolled in the study, with the same distribution of the phase I. Enrolled GPs will be
instructed to invite all patients meeting the eligibility criteria.
Data collection The collection of the data will occur in June 2018. Patient's
socio-demographic and clinical characteristics and medication will be registered using the
same methodology as described in phase I. The investigators will also collect outcome
measures of some tests.
Statistical analysis Descriptive statistics will be computed for all variables together with
95% CI whenever relevant and applicable. Associations between qualitative-independent
variables will be tested using χ2 test. Comparisons between two or more independent groups
regarding a quantitative variable are to be conducted using analysis of variance (ANOVA) or
Kruskal-Wallis non-parametric test, if normality assumption is not met. ANCOVA may also be
used to adjust for potential confounding factors. Associations between quantitative
independent variables will be analysed using Pearson's or Spearman's correlation coefficient
depending on normality assumption. All tests will be two-sided, considering a significance
level of 0.05.
Phase III: impact of enablement of older adults in their willingness to deprescribe and
quality of life Design Non-pharmacological randomised clinical study, intended to last for
six months.
Setting Primary Care Centres in Portugal will be randomly selected from six Health Centres of
Centre of Portugal (Aveiro, Castelo Branco, Coimbra, Guarda, Leiria and Viseu)
Sample size Will be created two groups with a minimum of 190 patients each (one will be the
intervention group and the other the control).
Study procedures This phase of the study is expected to start in September 2019 and will last
for 6 months.
Again, GPs sampling will be made according to existing files and those who accept to
participate will recruit their own patients. Patients from previous phases can be enrolled in
phase III. Assuming that a GP will be able to include at least 6 patients, a total of 64 GPs
has to be enrolled in the study. Enrolled GPs will be instructed to invite all patients
meeting the eligibility criteria.
Two groups will be created with a minimum of 190 patients each, one of which will be composed
from patients from the region of Aveiro, Coimbra and Guarda and the other from patients from
the region of Castelo Branco, Leiria and Viseu. In the intervention group the investigators
will give enablement tools and talks with their GPs about how to issue the problem of
polypharmacy. The information given in this group will result from the knowledge obtained in
phase II in the shape of small leaflets and other information materials to be made according
to the best practice, to be given and remembered at scheduled times to the intervention
group.
Data collection The collection of the data will occur in the beginning and end of phase II.
Patient's socio-demographic and clinical characteristics and medication will be registered
using the same methodology as described in phase I. The investigators will also collect
outcome measures of applied tests.
Statistical analysis Descriptive statistics will be computed for all variables together with
95% CI whenever relevant and applicable. Associations between qualitative-independent
variables will be tested using χ2 test. Comparisons between two or more independent groups
regarding a quantitative variable are to be conducted using analysis of variance (ANOVA) or
Kruskal-Wallis non-parametric test, if normality assumption is not met. ANCOVA may also be
used to adjust for potential confounding factors. Associations between quantitative
independent variables will be analysed using Pearson's or Spearman's correlation coefficient
depending on normality assumption. All tests will be two-sided, considering a significance
level of 0.05.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03688542 -
Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module
|
N/A | |
Completed |
NCT02545257 -
Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care
|
N/A | |
Withdrawn |
NCT01932632 -
Medication Minimization for Long-term Care Residents
|
N/A | |
Recruiting |
NCT04615065 -
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
|
||
Active, not recruiting |
NCT04181879 -
Appropriate Polypharmacy in Older People in Primary Care
|
N/A | |
Completed |
NCT02918058 -
Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults
|
N/A | |
Completed |
NCT03655405 -
Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents
|
N/A | |
Completed |
NCT04575155 -
Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management
|
N/A | |
Withdrawn |
NCT05816967 -
Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients
|
N/A | |
Completed |
NCT05616689 -
Bundled Hyperpolypharmacy Deprescribing
|
N/A | |
Terminated |
NCT04055896 -
Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting
|
N/A | |
Active, not recruiting |
NCT03052192 -
Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
|
||
Completed |
NCT02866799 -
Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy
|
N/A | |
Completed |
NCT01732302 -
Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients
|
N/A | |
Enrolling by invitation |
NCT05053815 -
Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
|
||
Active, not recruiting |
NCT04585191 -
Reducing Treatment Risk in Older Adults With Diabetes
|
N/A | |
Active, not recruiting |
NCT04120480 -
Effectiveness of PGx Testing
|
N/A | |
Recruiting |
NCT05609981 -
Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems
|
N/A | |
Recruiting |
NCT05501223 -
Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic
|
N/A | |
Completed |
NCT05628181 -
A Patient-facing Tool to Reduce Opioid-Psychotropic Polypharmacy in People Living With Dementia (PLWD)
|
N/A |